FASTER
Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 100 patients (estimated)
- Sponsors
- Sarah Cannon Research Institute
- Collaborators
- Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT), Pfizer
- Tags
- Autologous Stem Cell Transplant, Bispecific Antibody, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2169
- NCT Identifier
- NCT06974786
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.